4.3 Article

Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0b013e3181d05579

关键词

antiretroviral therapy; renal toxicity; reversibility; tenofovir

资金

  1. Abbott
  2. Gilead
  3. GlaxoSmithKline
  4. Merck
  5. Bristol-Myers Squibb
  6. Gilead Sciences
  7. Roche
  8. Boehringer-Ingelheim

向作者/读者索取更多资源

Background: Significant nephrotoxicity develops in 1%-2% of HIV-infected adults receiving tenofovir (TDF). This nephrotoxicity is said to resolve rapidly, but this assessment is based on short follow-up, very few patients and use of serum creatinine, an insensitive measure of renal function. Methods: We determined the reversibility of TDF-related nephrotoxicity in 24 HIV-infected male outpatients who ceased TDF for renal impairment by retrospective assessment of estimated glomerular filtration rate (eGFR) using the Modified Diet in Renal Disease equation. Results: Median (interquartile range) eGFR pre-TDF was 74 (6188) mL.min(-1) . 1.73 m(-2), fell to 51 (39-61) mL.min(-1) . 1.73 m(-2) at TDF cessation and increased to 58 (48-70) mL.min(-1) . 1.73 m(-2) a median 13 months after TDF cessation (most recent vs pre-TDF eGFR; P = 0.0008). Results were similar with the Cockcroft-Gault equation and after exclusion of patients who had shorter follow-up after TDF cessation. Only 10 (42%) patients reached their pre-TDF eGFR. Greater eGFR improvement was significantly associated with more rapid decline in eGFR on TDF therapy and in those who received TDF with a protease inhibitor, with a trend for shorter duration of TDF therapy. Discussion: In this population, TDF-related renal toxicity was not always fully reversible.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据